Future directions in haematology: Beyond multiple myeloma

Acta Haematologica

Volumn 114, Issue SUPPL. 1, 2005, Pages 27-32

  Prentice, H Grant ^a,b   Sacchi, Stephano ^c   Russell, Nigel ^d  

^a CELGENE CORPORATION   (United States)

^b Pharmion Ltd   (United Kingdom)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Haematology; Mantle cell lymphoma; Myelodysplastic syndromes; Myelofibrosis; Primary amyloidosis; Waldenstr m's macroglobulinaemia

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; HEMOGLOBIN; IDARUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; RITUXIMAB; THALIDOMIDE; THALIDOMIDE DERIVATIVE; VINCRISTINE;

ACUTE MYELOBLASTIC LEUKEMIA; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTONOMIC NEUROPATHY; BLOOD TRANSFUSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; CYTOTOXIC T LYMPHOCYTE; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; DRUG ERUPTION; FATIGUE; HEART FAILURE; HEMATOLOGY; HUMAN; LUNG EDEMA; LUNG EMBOLISM; LYMPHADENOPATHY; LYMPHOMA; MANTLE CELL LYMPHOMA; META ANALYSIS; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NATURAL KILLER CELL; NEUTROPENIA; NONHODGKIN LYMPHOMA; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; RECORDING; SOMNOLENCE; SPLEEN SIZE; THROMBOCYTE; VENOUS THROMBOEMBOLISM; WALDENSTROEM MACROGLOBULINEMIA;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOOD TRANSFUSION; CLINICAL TRIALS, PHASE II; CYTOKINES; DISEASE-FREE SURVIVAL; EUROPEAN UNION; HEMATOLOGY; HEMOGLOBINS; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOCYTE ACTIVATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROMES; ORGAN SIZE; REMISSION INDUCTION; SPLEEN; T-LYMPHOCYTES; THALIDOMIDE; WALDENSTROM MACROGLOBULINEMIA;

EID: 24944487190     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087042     Document Type: Article

References (26)

1. Raza A, Meyer P, Dutt D, et al: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001;98:958-965.
2. Zorat F, Shetty V, Dutt D, et al: The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 2001;4:881-894.
3. Mufti G, List A, Gore S, Ho A: Myelodysplastic syndrome. Hematology (Am Soc Hematol Educ Program) 2003;176-199.
4. Saunthararajah Y, Nakamura R, Nam J, et al: HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002;100:1570-1574.
5. Strupp C, Germing U, Scherer A, et al: Thalidomide for the treatment of idiopathic myelofibrosis. Eur J Haematol 2004;72:52-57.
6. Piccaluga P, Visani G, Pileri S, et al: Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid mateplasia. A pilot study. Leukemia 2002;16:1609-1614.
7. Mesa R, Steensma D, Pardanani A, et al: A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101:2534-2541.
8. Barosi G, Elliot M, Canepa L, et al: Thalidomide in myelofibrosis with myeloid metaplasia: a pooled analysis of individual patient data from five studies. Leuk Lymphoma 2002;43:2301-2307.
9. Spivak J, Barosi G, Tognoni G, et al: Chronic myeloproliferative disorders. Hematology (Am Soc Hematol Educ Program) 2003;200-224.
10. Merup M, Kutti J, Birgergard G, et al: Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. Med Oncol 2002;19:79-86.
11. Thomas D, Estey E, Giles F, et al: Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol 2003;123:436-441.
12. Steins M, Bieker R, Padro T, et al: Thalidomide for the treatment of acute myeloid leukemia. Leuk Lymphoma 2003;44:1489-1493.
13. Lowdell M, Craston R, Samuel D, et al: Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural kille cells. Br J Haematol 2002;117:821-827.
14. Davies F, Raje N, Hideshima T, et al: Thalidomide and immunomodulatory derivative augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:3495-3496.
15. Kay N, Geyer S, Yaqoob I, et al: Thalidomide (Td) treatment in chronic lymphocytic leukemia (CLL): A North Central Cancer Treatment Group (NCCTG) Study. Blood 2003;102:5162 (Abstract).
16. Chanan-Khan A, Fallon A, Miller K, et al: Thalidomide (T) and Fludarabine (F) as front-line therapy for patients (pts) with previously untreated chronic lymphocytic leukemia (CLL): results of a phase I trial. Blood 2003;102:2502 (Abstract).
17. Dispenzieri A, Lacy M, Rajkumar S, et al: Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003;10:257-261.
18. Seldin D, Choufani E, Dember L, et al: Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 2003;3:241-246.
19. Myers B, Lachmann H, Russell NH: Novel combination chemotherapy for primary (AL) amyloidosis; clinical, laboratory and serum amyloid protein scan improvement. Br J Haematol 2003;121:803-805.
20. Wilson EA, Jobanputra S, Jackson R, Parker AN, McQuaker IG: Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report. Br. J Haematol 2002;119:128-130.
21. Damaj G, Lefrère F, Delarue R, et al: Thalidomide therapy response in relapsed mantle cell lymphoma. Leukemia 2003;17:1914-1915.
22. Kaufmann H, Raderer M, Woehrer S, et al: Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004;104:2269-2271.
23. Pro B, Younes A, Albitar M, et al: Thalidomide for patients with recurrent lymphoma. Cancer 2004;100:1186-1189.
24. Rule SAJ, Copplestone JA, Hamon MD, et al: Single agent thalidomide has significant activity in mantle cell lymphoma. Br J Haematol 2003;121:144.
25. Rule SAJ: Private communication. Department of Haematology and Oncology, Derriford Hospital, Plymouth, UK.
26. Dimopoulos M, Zomas A, Viniou N, et al: Treatment of Waldenstrom's macroglobulinemia with thalidomide. J Clin Oncol 2001;19:3593-3595.